Drug Trial Radar · NCT04496349
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Last checked: Nov 19, 2026Latest source record: Nov 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Jul 12, 2021
Primary completion
May 31, 2026
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Ascentage Pharma Group Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.
Conditions
- T-Prolymphocytic Leukemia
- Non-Hodgkins Lymphoma
Interventions
APG-115Drug
QOD, 2 weeks on, 1 week off, in repeated 21-day cycles
APG-2575Drug
APG-2575 given orally each day in cycle, in repeated 21-day cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose of APG-115Time frame: 21 days
- Maximum tolerated dose of APG-115+APG-2575Time frame: 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MD Anderson
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.